Skip to main content
A- A+
Advancing transformative RNA therapies for inherited retinal diseases

Advancing transformative RNA therapies
for inherited retinal diseases

Learn more


Sepul Bio is developing Sepofarsen and Ultevursen for debilitating genetic eye diseases such as LCA10 and Usher2a.

Sepul Bio is dedicated to innovation and the advancement of therapies in the hope of providing treatment options for rare genetic eye diseases.

Learn more

A Vision for the Future

Our projects are driven by the vision of a future where patients with inherited eye diseases have treatment options for their eye condition.  Through ongoing research and rigorous development, Sepul Bio hopes to bring new therapies to patients.


Sepul Bio is a business unit within Théa exclusively focused on developing treatments for inherited retinal diseases.  Sepul Bio’s initial focus will be to develop two flagship assets: Sepofarsen and Ultevursen.

Sepofarsen is an investigational RNA therapy targeting Leber congenital amaurosis 10. This therapy is designed to address vision problems by addressing the underlying genetic mutation. Sepofarsen aims to skip aberrant mutation in the mRNA, leading to the production of functional protein. Ultevursen, also based on RNA technology, is aimed at addressing vision loss in Usher syndrome type 2a and non-syndromic retinitis pigmentosa.

Learn more